Please login to the form below

Not currently logged in

After Axovant shock, Roivant pens diabetes deal with Poxel

Acquires Merck Serono’s diabetes candidate imeglimin as part of the deal

Gilead’s triple HIV drug approval prompts GSK lawsuit

ViiV HealthcareViiV claims bictegravir infringes its patent estate

J&J takes option on Theravance’s JAK drug in $1bn deal

TD-1473 has potential treating ulcerative colitis, Crohn’s and IBD patients

AZ expects return to growth this year after 2017 decline

AstraZeneca AZ headquarters London UKSoriot says the pharma company is 'turning a corner'

Roche faces biosimilar blitz in 2018

Roche Basel SwitzerlandAnalysts predict copycat competitors will slow the Swiss group’s revenue growth

Amazon's healthcare move takes aim at US costs

AmazonFounder Jeff Bezos says it enters the realm ‘open-eyed’ about its difficulty

Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi

Sanofi receptionThe offer comes at a 110% premium on the Belgian biopharma’s share price

AZ’s COPD triple data sets up market clash with GSK

AstraZeneca AZKRONOS trial showed significant improvements in lung function tests over two-drug combos

Biogen cuts $217m deal for Karyopharm neurology drug

Biogen Idec buildingThe biotech hopes to begin phase I trials of KPT-350 by the end of the year

Business in the USAHealth coverage across state lines

Despite a total lack of legislative wins, the new administration has made its presence felt at home and abroad

  • Ho_Ung_KimStanding out in a crowd

    Celltrion Healthcare’s Ho-Ung Kim on pricing, market access and regulatory challenges for successfully developing biosimilars

  • HeadsThe diseased organisation

    Like humans, organisations can be afflicted by genetic disorders that hinder performance and threaten survival but these can be understood and cured

Featured jobs

Subscribe to our email news alerts


Add my company

With a network of more than 27,000 employees conducting business in approximately 100 countries, we have helped develop or commercialize...

Latest intelligence

Finding the patient voice
How patients feel and speak about clinical trials...
Six Factors to Consider When Designing Advisory Boards
The good, the bad and the ugly
Tracking the pharmaceutical industry’s 2017 evolution and assessing how things may shape up in 2018 - it’s a trilogy of trends...